L3VLUP
ProSign in

FATE in the 13F filings

Fate Therapeutics Inc · CUSIP 31189P102

Sector · Pharmaceuticals and biotechnologyTheme · Biological productsTheme · Healthcare: biopharma and medtech· L3VLUP-defined
Quarter
Q1 2025Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022
Quarter end
31 Dec 2022
the date the book describes
Filed
10 Mar 2023
latest of these filings; the earliest 24 Jan 2023
Managers listing it
5
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q3 2022 and Q4 2022; 4 listed it in both
Shares listed
11,471,220
combined, among listed positions
Reported value
$116m
combined, at the quarter end

Managers listing FATE in Q4 2022

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q3 2022, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

5 of 5 holders

ActionFiling
Capital World Investors5,591,517$56munder 0.1%Trimmed-2,639,79514 Feb 2023 (the filing on sec.gov)
ARK Investment Management LLC4,214,863$43m0.37%Trimmed-7,440,97024 Jan 2023 (the filing on sec.gov)
Two Sigma Investments LP1,503,750$15munder 0.1%Addedn.a.14 Feb 2023 (the filing on sec.gov)
Woodline Partners LP160,718$1.6munder 0.1%Held014 Feb 2023 (the filing on sec.gov)
Baillie Gifford & Co372$4kunder 0.1%Held010 Mar 2023 (the filing on sec.gov)

Largest increases and reductions, by shares

Q3 2022 to Q4 2022, among managers that listed it in both quarters or opened it.

Increases

No increase among listed positions.

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
2 in Q1 2023 to 1 in Q1 2025

Tracked managers listing it, at least.

05101520142019202020212022202320242025
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
FATE by quarter
QuarterHoldersReported valueBuyersSellers
Q4 20131$3.4mn.a.n.a.
Q1 20141$2.7mn.a.n.a.
Q2 20141$1.6mn.a.n.a.
Q3 20141$880kn.a.n.a.
Q3 20182$11mn.a.n.a.
Q4 20181$28mn.a.n.a.
Q1 20192$53mn.a.n.a.
Q2 20194$108mn.a.n.a.
Q3 20195$112mn.a.n.a.
Q4 20193$68mn.a.n.a.
Q1 20204$153mn.a.n.a.
Q2 20209$454mn.a.n.a.
Q3 20208$446mn.a.n.a.
Q4 202011$2.0bnn.a.n.a.
Q1 202110$2.1bnn.a.n.a.
Q2 202111$2.1bnn.a.n.a.
Q3 20219$1.3bnn.a.n.a.
Q4 20217$971mn.a.n.a.
Q1 20227$677mn.a.n.a.
Q2 20226$520mn.a.n.a.
Q3 20227$494mn.a.n.a.
Q4 20225$116mn.a.n.a.
Q1 20232$483kn.a.n.a.
Q2 20232$4.5mn.a.n.a.
Q3 20233$4.9mn.a.n.a.
Q4 20232$10.0m20
Q1 20245$51m41
Q2 20243$10m12
Q3 20243$17m12
Q1 20251$6.2m10

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

FATE and GILD →FATE and AMGN →FATE and ARGX →Choose a stock to compare with FATE →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own FATE, latest filings →Back to the 13F Explorer →